Chronic Granulomatous Disease (CGD)
A rare inherited immune disorder in which certain white blood cells cannot kill specific bacteria and fungi effectively, leading to recurrent serious infections and granuloma formation.
- Rare Primary Immunodeficiency
- Infection Prevention Focus
- Specialist Transplant Evaluation
- Inheritance Pattern
- X-linked or Autosomal Recessive
- Most Common Form
- X-linked (CYBB) ~65% of Cases
- Key Defect
- Impaired NADPH Oxidase Function
- Curative Option
- Hematopoietic Stem Cell Transplant
Condition Overview
Chronic Granulomatous Disease (CGD) is a rare inherited primary immunodeficiency caused by mutations affecting the NADPH oxidase enzyme complex, which certain white blood cells called phagocytes normally use to produce reactive oxygen species and kill ingested bacteria and fungi.
Without this killing mechanism working properly, people with CGD are prone to recurrent, sometimes severe, bacterial and fungal infections affecting the lungs, lymph nodes, liver, skin, and bone. The body's attempt to wall off persistent organisms often leads to the formation of granulomas, clusters of immune cells, which can themselves cause complications such as bowel or urinary tract obstruction.
CGD can be inherited in an X-linked pattern (more common and often more severe, predominantly affecting males) or an autosomal recessive pattern (generally somewhat milder, affecting both sexes equally). With modern infection prevention and, increasingly, curative stem cell transplant, outcomes have improved substantially over recent decades.
Types and Subtypes
CGD is classified by which component of the NADPH oxidase complex is affected and the resulting inheritance pattern.
Symptoms and Signs
CGD typically presents in early childhood with recurrent infections involving a characteristic set of organs and pathogens, though milder forms can present later.
Causes and Risk Factors
CGD is caused by mutations in one of several genes encoding components of the NADPH oxidase enzyme complex, which phagocytic immune cells need to generate the reactive oxygen burst that kills certain bacteria and fungi.
Diagnosis and Investigations
Diagnosis of CGD relies on functional testing of phagocyte killing ability, supported by genetic confirmation.
Disease Severity Stratification
CGD does not use a tumor staging system; severity is generally classified by genetic subtype, residual NADPH oxidase activity, and infection history, which together guide management intensity.
Standard Treatment Options
Management of CGD combines lifelong infection prevention with prompt, often prolonged, treatment of breakthrough infections, alongside consideration of curative stem cell transplant.
Advanced and Emerging Treatment Options
Beyond standard prophylaxis, curative cellular therapy and gene-targeted approaches are increasingly part of the CGD treatment landscape.
Cellular Therapy
Hematopoietic Stem Cell Transplant
Offers a potential cure by replacing the defective immune system with donor cells capable of normal NADPH oxidase function; outcomes have improved substantially with modern conditioning approaches.
Gene Therapy
Investigational Gene Therapy for CGD
Approaches using a patient's own corrected stem cells are being studied as an alternative to donor transplant, particularly for patients without a suitable matched donor.
Immune-Supportive Therapy
Interferon-Gamma Therapy
Used in some patients to help enhance phagocyte function and reduce serious infection frequency alongside antimicrobial prophylaxis.
Precision Medicine
Genetic Subtype-Guided Management
Identification of the specific NADPH oxidase gene affected increasingly informs individualized prophylaxis and transplant timing decisions.
Biomarkers & Precision Medicine
Functional and genetic testing are central both to confirming CGD and to understanding its likely severity and treatment response.
When a Second Opinion May Be Important
Given the rarity of CGD and the complexity of both infection management and transplant decisions, specialist input is valuable at several stages.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Outcomes in CGD have improved substantially over recent decades with modern antimicrobial prophylaxis, earlier diagnosis, and growing access to curative stem cell transplant, though the disease still carries meaningful lifelong infection risk for many patients.
Supportive Care and Living With Chronic Granulomatous Disease
Living with CGD involves consistent attention to infection prevention, prompt treatment of new symptoms, and broader support for patients and families.
How CancerFax Helps You Explore Treatment Options
CancerFax can help you organize medical reports for specialist immunology review, coordinate a second opinion, and connect you with transplant centers experienced in Chronic Granulomatous Disease and related primary immunodeficiencies.
Get a free case reviewFrequently Asked Questions
CGD is a rare inherited immunodeficiency in which certain white blood cells cannot effectively kill specific bacteria and fungi, leading to recurrent infections and granuloma formation.
CGD is caused by mutations in genes that make up the NADPH oxidase enzyme complex, which phagocytic immune cells need to generate the reactive oxygen burst that kills certain organisms.
Yes, it can be inherited in an X-linked pattern, predominantly affecting males, or in an autosomal recessive pattern affecting both sexes equally.
Diagnosis relies on functional testing of phagocyte killing ability, most commonly the dihydrorhodamine (DHR) flow cytometry assay, confirmed with genetic testing.
People with CGD are particularly susceptible to certain bacteria, such as Staphylococcus aureus, and fungi, particularly Aspergillus species, affecting the lungs, skin, lymph nodes, and liver.
Lifelong antimicrobial prophylaxis is the foundation of treatment, with hematopoietic stem cell transplant offering a potential cure for the underlying immune defect.
Hematopoietic stem cell transplant can cure the underlying immune defect in CGD, and investigational gene therapy is being studied as an alternative for patients without a matched donor.
Because phagocytes cannot fully clear certain organisms, the immune system forms granulomas in an attempt to wall off persistent infection, which can themselves cause complications such as bowel or urinary obstruction.
Care typically involves a multidisciplinary team including clinical immunology, infectious disease, and, when transplant is considered, transplant medicine.
Yes. CancerFax can help you organize your medical reports for specialist review, coordinate a second opinion with immunologists experienced in CGD, and support cross-border coordination if stem cell transplant or investigational gene therapy access is being considered.
Get Expert Guidance for Chronic Granulomatous Disease
Whether managing recurrent infections or considering stem cell transplant, CancerFax can help connect you with the right specialists.